1022 AavantiBio launch
BioCentury & Getty Images


Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

Oct 23, 2020 | 12:41 AM GMT

With $107 million in fresh series A cash, gene therapy company AavantiBio will develop a program for Friedreich’s ataxia with leadership joining from Sarepta, which joined the A round.

Co-founded by a pair of gene

Read the full 633 word article

How to gain access

Continue reading with a
two-week free trial.